Shape Our Content: Take The Reader Survey

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

woman filling in satisfaction engagement survey on laptop
• Source: Shutterstock: Munthita

We value your feedback and suggestions as we look to improve the format of our content and the way it is delivered to you. By completing our customer survey, you can provide your input on essential aspects of content and delivery.

The survey asks about your preferred content formats, such as articles, infographics, podcasts, data trackers and videos; how you access our content, e.g. email, website, PDF, mobile app and RSS; and coverage areas you value or would like to see more of.

We also want to hear about the accessibility and ease of use of our content, as well as your thoughts about features such as AI, audio articles and article translation. The survey results will help us decide what changes to format, delivery, product features and content coverage will be most valuable to you.

The survey should only take seven minutes to complete, and you get the chance to win an Amazon gift voucher just by taking part. The deadline for survey responses is 17 September.

Take the survey

To discuss the editorial content of In Vivo at any time, reach out to me at eleanor.malone@citeline.com.

More from Archive

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.